Geron Corp GERN
Institutional shares held
502 Million
643K
calls
276K
puts
Total value of holdings
$562M
$719K
calls
$309K
puts
Market Cap
$423M
377,819,008
Shares Out.
Institutional ownership
132.87%
# of Institutions
287
We take great care to ensure that the data presented and summarized in this overview for GERON CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GERN
View all-
Ra Capital Management, L.P. Boston, MA60.4MShares$67.6 Million1.42% of portfolio
-
Black Rock Inc. New York, NY46.6MShares$52.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT41.1MShares$46 Million1.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA34.4MShares$38.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$30.5 Million5.93% of portfolio
-
State Street Corp Boston, MA26.6MShares$29.8 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY21.3MShares$23.9 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT17.3MShares$19.4 Million1.44% of portfolio
-
Vestal Point Capital, LP New York, NY17.2MShares$19.3 Million1.07% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il15.7MShares$17.6 Million0.0% of portfolio
Latest Institutional Activity in GERN
Top Purchases
Top Sells
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Transactions at GERN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,702
+2.94%
|
$5,702
$1.37 P/Share
|
|
Jun 30
2025
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,540
+2.94%
|
$5,540
$1.41 P/Share
|
|
May 09
2025
|
V Bryan Lawlis Director |
BUY
Open market or private purchase
|
Direct |
13,300
+50.0%
|
$13,300
$1.18 P/Share
|
|
Mar 31
2025
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,913
+2.7%
|
$4,913
$1.59 P/Share
|
|
Feb 27
2025
|
James Ziegler EVP, Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.6 P/Share
|
|
Feb 27
2025
|
John A Scarlett Chairman, President and CEO |
BUY
Open market or private purchase
|
Direct |
12,500
+50.0%
|
$12,500
$1.76 P/Share
|
|
Feb 27
2025
|
Scott Alan Samuels EVP, Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+35.99%
|
$15,000
$1.61 P/Share
|
|
Dec 31
2024
|
Robert J. Spiegel Director |
SELL
Grant, award, or other acquisition
|
Direct |
2,206
-1.26%
|
-
|
|
Sep 30
2024
|
Robert J. Spiegel Director |
SELL
Grant, award, or other acquisition
|
Direct |
1,767
-1.03%
|
-
|
|
Jul 08
2024
|
Andrew J Grethlein EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
674,348
-100.0%
|
$2,697,392
$4.56 P/Share
|
|
Jul 08
2024
|
Andrew J Grethlein EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
674,348
+50.0%
|
$674,348
$1.72 P/Share
|
|
Jun 28
2024
|
Robert J. Spiegel Director |
SELL
Grant, award, or other acquisition
|
Direct |
1,916
-1.12%
|
-
|
|
Jun 10
2024
|
Anil Kapur EVP, Corp Strategy & CCO |
SELL
Open market or private sale
|
Direct |
421,875
-100.0%
|
$1,687,500
$4.64 P/Share
|
|
Jun 10
2024
|
Anil Kapur EVP, Corp Strategy & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
421,875
+50.0%
|
$421,875
$1.06 P/Share
|
|
Jun 10
2024
|
Faye Feller EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
287,900
-100.0%
|
$1,151,600
$4.63 P/Share
|
|
Jun 10
2024
|
Faye Feller EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
287,900
+50.0%
|
$287,900
$1.14 P/Share
|
|
Jun 04
2024
|
John A Scarlett Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
600,000
-50.0%
|
$2,400,000
$4.0 P/Share
|
|
Jun 04
2024
|
John A Scarlett Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+50.0%
|
$1,200,000
$2.54 P/Share
|
|
May 15
2024
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
35,000
-100.0%
|
$105,000
$3.75 P/Share
|
|
May 15
2024
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
$35,000
$1.94 P/Share
|
Last 12 Months Summary
Buy / Acquisition
157K
Shares
From
5
Insiders
| Open market or private purchase | 141K shares |
|---|---|
| Grant, award, or other acquisition | 16.2K shares |
Sell / Disposition
2.21K
Shares
From
1
Insiders
| Grant, award, or other acquisition | 2.21K shares |
|---|